These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 3823774)
1. [Hormonal treatment in cancer of the prostate]. Boccon-Gibod L Rev Prat; 1987 Feb; 37(7):386-90. PubMed ID: 3823774 [No Abstract] [Full Text] [Related]
2. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate]. Berenguer Sánchez A Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304 [No Abstract] [Full Text] [Related]
3. Complete androgen blockade for the treatment of prostate cancer. Labrie F; Dupont A; Belanger A Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740 [No Abstract] [Full Text] [Related]
4. Endocrine treatment of prostate cancer: standard treatment and new perspectives. Boccardo F; Pace M In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985 [TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy of prostate cancer: current concepts and future prospects. Smith JA Clin Ther; 1988; 10(3):281-6. PubMed ID: 3078908 [TBL] [Abstract][Full Text] [Related]
6. [Disseminated carcinoma of the prostate: monotherapy or complete androgenic blockade?]. González Martín M; Gómez Veiga F; Alvarez Castelo L Arch Esp Urol; 1997 Dec; 50(10):1067-76. PubMed ID: 9494195 [TBL] [Abstract][Full Text] [Related]
8. Principles of endocrine manipulation in the treatment of prostatic cancer. Neumann F Prog Clin Biol Res; 1985; 185A():73-98. PubMed ID: 3898136 [No Abstract] [Full Text] [Related]
9. [Hormonal receptors and other procedures for predicting clinical response in cancer of the prostate]. Habib FK; Chisholm GD Arch Esp Urol; 1984 Dec; 37 Suppl 2():751-9. PubMed ID: 6085672 [No Abstract] [Full Text] [Related]
10. Secondary hormonal therapy. Smith DC Semin Urol Oncol; 1997 Feb; 15(1):3-12. PubMed ID: 9050134 [TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216 [TBL] [Abstract][Full Text] [Related]
16. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer]. Tsukamoto S; Akaza H Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140 [TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen ablation as a treatment for prostate cancer. Wolff JM Front Radiat Ther Oncol; 2002; 36():66-71. PubMed ID: 11842756 [No Abstract] [Full Text] [Related]
18. Androgen deprivation therapy for precancerous lesions of the prostate. Hull D; Bostwick DG Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786 [TBL] [Abstract][Full Text] [Related]
19. [Cancer of the prostate: new hormone therapies]. Namer M; Boublil JL; Kather R; Cavaglione G Bull Cancer; 1986; 73(1):47-55. PubMed ID: 3779122 [TBL] [Abstract][Full Text] [Related]
20. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]